PCI Biotech: Last day of trading in subscription rights tomorrow

Oslo, 4 January 2017, Reference is made to the previous announcements by PCI
Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the fully
underwritten rights issue of 10,000,000 new shares in the Company (the "Rights
Issue"). The period of trading in subscription rights in the Rights Issue
expires at 16:30 CET tomorrow, 5 January 2017. The subscription rights are
tradable on Oslo Børs (symbol "PCIB T").

Any subscription rights that are not used to subscribe for new shares in the
Rights Issue or not sold prior to 16:30 CET on 5 January 2017, will lapse
without compensation to the holder and cease to carry any value.

Holders of subscription rights (whether granted or acquired) must, in order to
subscribe for new shares, submit a correctly completed subscription form to the
book-runners, Fondsfinans AS, as outlined below and included in the Prospectus.
Subscribers who are Norwegian residents with a Norwegian personal identification
number may also subscribe for shares through the VPS online subscription system
or by following the link on www.beringerfinance.com/deals/#filter=.ongoing,
which will direct the subscriber to the VPS online system.

Fondsfinans AS

Haakon VII's gate 2

P:O. Box 1782 Vika

NO-0122 Oslo, Norway

Fax: +47 23 11 30 03
E-mail: oppgjor@fondsfinans.no
www.beringerfinance.com/deals/#filter=.ongoing

The Subscription Form can be delivered by e-mail to the above e-mail address.

Please refer to the prospectus dated 13 December 2016 for further information.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
www.pcibiotech.com
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757.

Important Notice
The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company. The Company's financial advisor is acting
exclusively  for  the  Company  and  no  one  else, and will not be responsible
to  anyone  other  than  the  Company for providing the protections afforded  to
its clients, or for advice in  relation to the Rights Issue, the contents  of
this  announcement or  any of  the matters  referred to herein. The Rights Issue
and the distribution of this announcement and other information in connection
with the Rights Issue may be restricted by law in certain jurisdictions. The
Company assumes no responsibility in the event there is a violation by any
person of such restrictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about, and
to observe, any such restrictions.

The Rights Issue will not be made in any jurisdiction or in any circumstances in
which such offer or solicitation would be unlawful. This announcement is not for
distribution, directly or indirectly in or into any jurisdiction in which it is
unlawful to make any such offer or solicitation to such person or where prior
registration or approval is required for that purpose. No steps have been taken
or will be taken relating to the Rights Issue in any jurisdiction outside of
Norway in which such steps would be required. Neither the publication and/or
delivery of this announcement shall under any circumstances imply that there has
been no change in the affairs of the Company or that the information contained
herein is correct as of any date subsequent to the earlier of the date hereof
and any earlier specified date with respect to such information.

This publication is not an offer for sale of or the solicitation of an offer to
purchase securities in the United States. The Offer Shares and the Subscription
Rights have not been registered under the U.S. Securities Act of 1933, as
amended, or any state securities laws, and may not be offered or sold within the
United States.

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform.  PCI is
applied to three distinct anticancer paradigms: fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction
technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics
delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's lead fimaChem programme consists of a clinical Phase I/II clinical
study in bile duct cancer, an orphan indication with a high unmet need and
without approved products.  fimaVacc applies a unique mode of action to enhance
the essential cytotoxic effect of therapeutic cancer vaccines, which works in
synergy with several other state-of-the-art vaccination technologies.  fimaNAc
utilises the endosomal release to provide intracellular delivery of nucleic
acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.